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Abstract
Background and aim: The Pan-African Society of Cardiology 
(PASCAR) has identified hypertension as the highest area 
of priority for action to reduce heart disease and stroke 
on the continent. The aim of this PASCAR roadmap on 
hypertension was to develop practical guidance on how to 
implement strategies that translate existing knowledge into 
effective action and improve detection, treatment and control 
of hypertension and cardiovascular health in sub-Saharan 
Africa (SSA) by the year 2025. 
Methods: Development of this roadmap started with the 
creation of a consortium of experts with leadership skills in 
hypertension. In 2014, experts in different fields, including 
physicians and non-physicians, were invited to join. Via face-
to-face meetings and teleconferences, the consortium made a 
situation analysis, set a goal, identified roadblocks and solu-
tions to the management of hypertension and customised the 
World Heart Federation roadmap to Africa.
Results: Hypertension is a major crisis on the continent but 
very few randomised, controlled trials have been conducted 
on its management. Also, only 25.8% of the countries have 
developed or adopted guidelines for the management of 
hypertension. Other major roadblocks are either govern-
ment and health-system related or healthcare professional or 
patient related. The PASCAR hypertension task force identi-
fied a 10-point action plan to be implemented by African 
ministries of health to achieve 25% control of hypertension 
in Africa by 2025. 
Conclusions: Hypertension affects millions of people in SSA 
and if  left untreated, is a major cause of heart disease and 
stroke. Very few SSA countries have a clear hypertension 
policy. This PASCAR roadmap identifies practical and effec-
tive solutions that would improve detection, treatment and 
control of hypertension on the continent and could be imple-
mented as is or adapted to specific national settings. 
Keywords: hypertension, roadmap, Africa, prevalence, control, 
blood pressure, action
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Executive summary
The Word Health Organisation (WHO) estimated that the number 
of people affected by hypertension is highest in Africa, at about 
46% of adults aged 25 years and older, compared to 35 to 40% 
elsewhere in the world. Many hypertensive Africans are unaware 
of their status, and are rarely treated or poorly controlled, making 
them at highest risk for stroke, and heart and renal disease.
African Union member states at the 2004 Addis Ababa 
meeting described hypertension as one of the continent’s greatest 
health challenges after HIV/AIDS. An urgency was recognised to 
develop and share best practices, including affordable and effective 
community-based programmes to screen and treat hypertension.
The WHO’s 2013–2020 global action plan calls upon the 
United Nations (UN) member states to take immediate action in 
preventing and controlling non-communicable diseases (NCDs). 
Target six of the action plan aims to achieve a 25% relative 
reduction in the prevalence of raised blood pressure or to 
contain this by 2020, according to national circumstances. 
State and government heads in the UN Political Declaration 
are committed to preventing and controlling NCDs through 
the establishment and strengthening of multi-sectoral national 
policies and plans.
The Pan-African Society of Cardiology (PASCAR) met 
several times to identify key actions for a hypertension roadmap 
on the continent. The PASCAR coalition identified several 
roadblocks hampering the control of hypertension on the 
continent, which exist at government/health-system, physician 
and patient levels and include the following.
Government- and health system-related roadblocks 
•	 lack of established policies for controlling hypertension
•	 poor political willingness to implement policies on NCDs
•	 poor universal health insurance coverage, leading to out-of-
pocket payment by most patients, which leads to poor access 
and adherence to treatment
•	 lack of policies on antihypertensive medication procurement 
and distribution, resulting in stock shortages
•	 lack of ad hoc screening and proper referral systems for 
patients identified at routine screening 
•	 inability of governments to effectively work with the private 
sector, non-governmental organisations (NGOs) and academ-
ia in a coordinated plan to tackle the burden of hypertension.
Healthcare professional-related roadblocks
•	 lack of appropriate evidence-based guidelines for healthcare 
professionals in individual countries 
•	 hypertension treatment guidelines are poorly implemented 
because of a lack of continuing medical education
•	 a dearth of healthcare professionals (physicians, nurses and 
trained health workers) at primary care level with very low 
physician/patient ratio
•	 lack of quality and affordable antihypertension medications. 
Patient-related roadblocks
•	 poor awareness about hypertension and its consequences
•	 poor adherence to drug therapy because of limited access to 
medication 
•	 difficulty in changing lifestyles, and false health beliefs that 
hypertension is curable, due to poor patient education.
PASCAR 10-point action plan
The PASCAR hypertension task force identified a 10-point 
action plan, to be implemented by African ministries of health to 
achieve 25% control of hypertension in Africa by 2025.
1. All NCD national programmes should additionally contain 
a plan for the detection of hypertension.
2. Allocate appropriate funding and resources for the early 
detection, efficient treatment and control of hypertension.
3. Create or adopt simple and practical clinical evidence-based 
hypertension management guidelines.
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4. Annually monitor and report the detection, treatment and 
control rates of hypertension, with a clear target of improve-
ment by 2025, using the WHO STEPwise surveillance in all 
countries.
5. Integrate hypertension detection, treatment and control 
within existing health services, such as vertical programmes 
(e.g. HIV, TB).
6. Promote a task-sharing approach with adequately trained 
community health workers (shift-paradigm).
7. Ensure the availability of essential equipment and medicines 
for managing hypertension at all levels of care.
8. Provide universal access and coverage for detecting, treating 
and controlling hypertension.
9. Support high-quality research to produce evidence that will 
guide interventions.
10. Invest in population-level interventions for preventing hyper-
tension, such as reducing high levels of salt intake and 
obesity, increasing fruit and vegetable intake and promoting 
physical activity.
African ministries of health, in their leadership roles, are called 
to adopt the 10-point action plan and customise it at a country 
level using a multi-sectoral approach. PASCAR calls on NGOs, 
all fraternal organisations, healthcare leaders and other members 
of  the international community to join in this ambitious 
endeavour to support efforts by African ministries of health 
in reducing the burden of hypertension in Africa. Effective 
advocacy towards policy makers and politicians in national 
governments is particularly encouraged. 
Hypertension definitions
There is a graded relationship between blood pressure (BP) 
levels, as low as 115/75  mmHg, and cardiovascular disease 
(CVD) risk.1 However, hypertension is defined as the BP level 
above which treatments have been shown to reduce clinical 
events in randomised trials, which is accepted as ≥ 140 mmHg 
systolic and/or ≥ 90  mmHg diastolic BP. The classification of 
BP levels used for defining hypertension is presented in Table 1. 
Hypertension burden in Africa
Hypertension has progressively become a major threat to the 
well-being of people in sub-Saharan Africa (SSA). During the 
past four decades, the highest levels of BP worldwide have shifted 
from high-income countries (HIC) to low- and middle-income 
countries (LMIC) in South Asia and SSA.2 The WHO estimates 
that the prevalence of hypertension is highest in the African 
region, with about 46% of adults aged 25 years and older being 
hypertensive.3 This compares to 35% in the Americas and other 
HIC and 40% elsewhere in the world.3 
High hypertension rates, ranging from 19.3% in Eritrea to 
39.6% in the Seychelles, were reported for 20 African countries 
in WHO STEPS (STEPwise approach to surveillance) surveys 
conducted between 2003 and 2009.4 In a systematic review, the 
pooled prevalence in over 110 414 participants aged ± 40 years 
in 33 surveys was 30% (95% confidence interval: 27–34%).5 In 
Table 1. Definitions of classes of raised blood pressure
Category SBP (mmHg) DBP (mmHg)
Optimal < 120 < 80
Normal 120–129 80–84
High normal 130–139 or 85–89
Grade 1 hypertension (mild) 140–159 or 90–99
Grade 2 hypertension (moderate) 160–179 or 100–109
Grade 3 hypertension (severe) ≥ 180 or ≥ 110
Isolated systolic hypertension ≥ 140 and < 90
SBP, systolic blood pressure; DBP, diastolic blood pressure
Arm supported at 
the level of the heart
Do not speak during 
the measurement
Put cuff on bare arm,  
3 cm above the elbow
Be seated, with back 
supported by the chair
BP measurement
• Prepare the patient
• Choose the appropriate cuff size
• Place the cuff and check that the tightness of the cuff is appropriate
• Press the start button
• The cuff will inflate and deflate, at the end of the measurement systolic, diastolic BP and pulse rate will be displayed
• Record the reading, then deflate the cuff
• Repeat the measurement after 1 minute
• Take two readings and obtain the average
Legs uncrossed
Feet supported by the ground
Patient preparation
• No caffeine, smoking or alcohol 
for preceding 30 minutes
• A quiet warm setting is required
• Bladder and bowel should be 
emptied
• No exogenous adrenergic 
stimulatns e.g. nasal 
decongestants or eye drops for 
papillary dilation
• Patient should be calmly seated 
for 5 minutes
If ausculatory method is used, more info 
on technique can be sought at https://www.
youtube.com/watch?v=-LqKmrmaHsk
Fig. 1.  PASCAR recommendations for blood pressure measurement, thresholds and action required following appropriate office measurement.
CARDIOVASCULAR JOURNAL OF AFRICA • Volume 28, No 4, July/August 2017AFRICA 265
Africa, the number of people with hypertension increased from 
54.6 million in 1990 to 92.3 million in 2000, and 130.2 million 
in 2010. Under prevailing circumstances, this could increase to 
216.8 million by 2030.6 
Gap in the care versus opportunity to control 
hypertension
The PASCAR task force recommends key steps for appropriate 
office measurement (Fig. 1). BP-lowering strategies that have 
shown their efficacy in HIC are likely to succeed in Africa. In 
Table 2, a synopsis is provided of currently published treatment 
guidelines differing regarding treatment thresholds. 
A simple and practical treatment algorithm using these 
thresholds is recommended (Fig. 2). Our schedule should 
consider patient costs (including transport and loss of wages 
because of time off to attend clinic visits), which affect treatment 
adherence and burden to the healthcare system. 
Because of the asymptomatic nature of hypertension, long-
term medication adherence is poor. Patients and healthcare 
practitioners must be educated on non-pharmacological BP 
control methods (see Fig. 2). We encourage patient education 
using text messages, e-mails or social media (WhatsApp 
or Facebook), all of which are progressively available and 
affordable in Africa. We also encourage face-to-face education 
by traditional and religious leaders.
Table 2. Blood pressure guidelines
WHO PEN1 NICE 20112 ESH/ESC 20133
ASH/ISH 
20144
AHA/ACC/ 
CDC 20135
US JNC 8 
20146
South Africa 
20157 Egypt 20138
Definition of 
hypertension 
(mmHg)
≥ 140/90 ≥ 140/90 and 
daytime ABPM 
(or home BP)  
≥ 135/85
≥ 140/90 ≥ 140/90 ≥ 140/90 Not addressed ≥ 140/90 ≥ 140/90 (high risk) – 
150/95 (low risk) and 
daytime ABPM (or 
home BP) ≥ 135/85
Drug therapy in 
low-risk patients 
after non-pharma-
cological treatment 
(mmHg)
> 160/100 ≥ 160/100 or 
daytime ABPM 
≥ 150/95
≥ 140/90 ≥ 140/90 ≥ 140/90 < 60 years, ≥ 
140/90;
≥ 60 years, ≥ 
150/90
≥140/90 ≥ 140/90 for high risk 
and ≥ 160/100 for low 
risk
First-line therapy < 55 years, low-
dose thiazide 
diuretic and/or 
ACE inhibitor;
≥ 55 years, CCB 
and/or low-dose 
thiazide diuretic
< 55 years, 
ACE inhibitor 
or ARB; ≥ 55 
years or African 
ancestry, CCB 
ACE inhibitor or 
ARB; beta-blocker; 
CCB; diuretic
Low-dose 
diuretic
ACE inhibi-
tor or ARB; 
CCB; diuretic
CCB/diuretic 
in people 
of African 
ancestry
ACE inhibi-
tor or ARB; 
CCB; diuretic
CCB/diuretic 
in people 
of African 
ancestry
Any of diuretics, beta-
blockers, CCB, ACEIs 
or ARBs. preferably 
a thiazide diuretic. In 
elderly (> 65 years) or 
in blacks, start with 
diuretic or CCB. 
Beta-blockers as 
first-line drug
No No (step 4) Yes (in specific 
subgroups)
No (step 4) No (step 3) No (step 4) No (step 4) Yes, in specific e.g. 
young, particularly 
those with tachycardia
Diuretic Thiazides, Chlortalidone, 
indapamide
Thiazides, chlortali-
done, indapamide
Thiazides, 
chlortalidone, 
indapamide
Thiazides Thiazides, 
chlortalidone, 
indapamide
Thiazide or 
thiazide-like 
(indapamide)
Thiazides, chlortha-
lidone, amiloride or 
spironolactone
Initiate drug 
therapy with two 
drugs (mmHg)
Not mentioned Not mentioned In patients with 
markedly elevated 
BP or patients with 
high overall CV risk
≥ 160/100 ≥ 160/100 ≥ 160/100 ≥ 160/100 Diuretic + beta-block-
ers/CCB/ACEIs/ARBs 
if  BP > 170/105
Blood pressure 
target (mmHg)
< 140/90 < 140/90;
≥ 80 years,  
< 150/90
< 140/90; elderly 
< 80 years, SBP 
140–150, SBP < 140 
in fit patients;
elderly ≥ 80 years, 
SBP 140–150
< 140/90;
≥ 80 years, < 
150/90
< 140/90; 
lower targets 
may be 
appropriate in 
some patients, 
including the 
elderly
< 60 years, < 
140/90;
≥ 60 years < 
150/90
< 140/90 < 150/95 in low-risk 
patients and in elderly 
(> 65 years).
< 140/90: ≥ 2 risk 
factors, CKD, TOD
< 130/80: HF or CKD 
when associated with 
proteinuria > 1 g/24 
hours.
Blood pressure 
target in patients 
with diabetes 
mellitus (mmHg)
< 130/80 Not addressed < 140/85 < 140/90 < 140/90; 
lower targets 
may be 
considered
< 60 years,
< 140/90;
≥ 60 years, < 
150/90
< 140/90 < 140/90 mmHg or < 
130/80 if  associated 
with proteinuria > 
1 g/24 hours
ABPM, ambulatory blood pressure monitoring; ACC, American College of Cardiology; ACE inhibitor, angiotensin converting enzyme inhibitor; AHA, American 
Heart Association; ARB, angiotensin receptor blocker; ASH, American Society of Hypertension; BP, blood pressure; CCB, calcium channel blocker; CDC, Centers for 
Disease Control and Prevention; CKD, chronic kidney disease; CV, cardiovascular; ESC, European Society of Cardiology; ESH, European Society of Hypertension; 
ISH, International Society of Hypertension; NICE, National Institute for Health and Care Excellence; SBP, systolic blood pressure; TOD, target-organ damage; US 
JNC 8, Eighth US Joint National Committee; WHO PEN, World Health Organisation Package of Essential Non-communicable disease interventions.
1World Health Organisation. Implementation tools: package of essential non-communicable (PEN) disease interventions for primary healthcare in low-resource settings. 
Available at: http://apps.who.int/iris/bitstream/10665/133525/1/9789241506557_eng.pdf. Accessed April 8, 2015.
2National Institute for Health and Care Excellence. NICE guidelines [CG127]. Hypertension: clinical management of primary hypertension in adults. Available at: www.
nice.org.uk/guidance/cg127/chapter/guidance. Accessed April 8, 2015.
3Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the task force for the management of arterial hyper-
tension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013; 34: 2159–2169. 
4Weber MA, Schiffrin EL, White WB, et al. Clinical practice guidelines for the management of hypertension in the community a statement by the American Society of 
Hypertension and the International Society of Hypertension. J Hypertens 2014; 32: 3–15. 
5Go AS, Bauman MA, Coleman King SM, et al. An effective approach to high blood pressure control: a science advisory from the American Heart Association, the 
American College of Cardiology, and the Centers for Disease Control and Prevention. J Am Coll Cardiol 2014; 63: 1230–1238. 
6James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to 
the Eighth Joint National Committee (JNC 8). J Am Med Assoc 2014; 311: 507–520.
7Seedat Y, Rayner B, Veriava Y. South African hypertension practice guideline 2014. Cardiovasc J Afr 2014; 25(6): 288–194.
8The Egyptian Hypertension Society: Egyptian hypertension guidelines. Egypt Heart J 2014; 66(2): 79–132.
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SCREENING
In health centre, clinic, hospital, pharmacy,  
markets and churches
CLINIC/HOSPITAL
By physicians and nurses. If ≥ 180/110 mmHg, refer. 
If < 140/90 mmHg, recheck after 6 months
Systolic BP of 140–159 or diastolic BP 90–99 mmHg 
without target-organ damage* and no diabetes
Systolic BP ≥ 160 or diastolic BP ≥ 100 mmHg
Systolic BP 140–159 or diastolic BP 90–99 mmHg 
AND diabetes/target-organ damage*
Encourage patient to carry out self-monitoring and 
adherence to medications
Advise the patient to inform the physician or  
health centre if he or she notices BP elevation  
or side effects
Patients should be advised to continue office visits 
6 monthly as clinically appropriate
Lifestyle modification** as a trial for 3–6 months. 
If this fails, consider adding a thiazide or thiazide-
like diuretic or long-acting CCB as monotherapy
Combination of two medications preferred:
thiazide or thiazide-like diuretic plus ACEI or ARB  
or CCB, or CCB plus ACEI or ARB” 
AND lifestyle modifications
Recheck and review readings in 3 months
ACEI: angiotensin converting enzyme inhibitors, ARB: angiotensin receptor blocker, CCB: calcium channel blocker
*Target-organ damage indicates people with evidence of hypertensive heart disease, stroke or renal disease. In these people and those with 
diabetes, ACEI or ARBs should be preferred. 
**Lifestyle modifications include a reduction in weight, a diet rich in fruits, vegetables and low fats, a moderation of alcohol consumption and 
smoking cessation, a lower sodium intake and a regular aerobic physical activity (at least 30 min per day for at least 5 days per week).
We emphasise that this algorithm does not replace the treating healthcare provider’s best clinical judgement. 
Recheck and review readings in 4 weeks
BP at goal (< 140/90 mmHg)?
Recheck and review readings in 4 weeks
NO
NO
YES
YES
If currently on BP medications optimise therapy or 
add drug from different classes.
If not on BP medications, commence thiazide or 
thizide-like diuretic
Consider referal to specialist if:
•	Patient with 3 medications (including a thiazide or 
thiazide-like diuretic) and BP not at goal
•	Secondary causes suspected
•	Heart disease, kidney disease, or stroke
•	BP > 180/110 mmHg
Optimise current dosages or add medications 
from a different class. Also consider adding 
spironolactone or a vasodilating beta-blocker or a 
long-acting α-blocker
Address adherence, advise on self-monitoring and 
request readings rom home and other settings.
BP at goal (< 140/90 mmHg)?
Fig 2. PASCAR hypertension treatment algorithm 
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The discrepancy between best practice (based on high-
quality evidence) and the care provided in routine clinical 
practice is called the ‘care gap’. This includes situations in 
which interventions with proven efficacy are under-utilised. This 
description is most marked in Africa, where it is favoured by 
poverty and inadequate utilisation of existing resources. Despite 
strong evidence of the management benefit, this can reflect as 
poor awareness and control of CVD rates or risk factors. 
Current data on awareness and hypertension control rates in 
SSA are from a wide range of studies differing in methodology 
and limiting the opportunity for reliable comparisons. However, 
available data show that the high prevalence of hypertension in 
Africa, as in other LMICs, is coupled with low awareness and 
control rates (Fig. 3), a reflection of a maximal care gap.5-8 
In 2011, UN member states acknowledged at the highest 
international level that premature deaths from NCDs reduce 
productivity and curtail economic growth, causing significant 
social challenges in most countries.9 In 2015, the previous target of 
25% reduction in rate of premature mortality from NCDs by 2025 
was extended to a reduction of 33% by 2030, through prevention, 
treatment and promotion of mental health and wellbeing.10
Since 2004, the African Union, in a pro-active approach, 
named hypertension one of the continent’s greatest health 
challenges after HIV/AIDS. After more than a decade, this 
political enthusiasm, which is crucial for the development and 
implementation of any healthcare policy, has yet to be translated 
into public health action. The role of hypertension experts is key 
to facilitate the states’ action to adequately contain this threat. 
In a simple and practical hypertension policy, the PASCAR 
approach emphasises working in collaboration with all other 
stakeholders to set clear goals and define priority actions and 
minimum standards of African healthcare systems.
The World Heart Federation roadmap and 
other relevant initiatives
As part of the WHO’s target in reducing heart attacks and 
stroke by 2025, the World Heart Federation (WHF) launched a 
roadmap focusing on raised BP during the 2015 World Health 
Assembly in Geneva.11 Herein the routes are described towards 
reducing premature cardiovascular mortality rate by 25%,11 
focusing on presenting practical steps for hypertension control. 
For effective hypertension control, four population groups were 
identified: people who are unaware of their BP status; those who 
are aware of having raised BP but it is uncontrolled; those who 
are aware of their raised BP, which is under control; and those 
who are aware of having normal BP. 
After identifying the target population, practical steps are 
provided for improving hypertension management. These include 
opportunistic screening for awareness of BP status and effective 
drug treatment for high BP. 
The use of generic antihypertensive medications rather than 
proprietary medications is encouraged, to substantially reduce 
the cost of care, but with a caveat for the need to ensure 
quality generic medications. Bearing in mind the holistic nature 
of healthcare delivery, this initiative identified health-system 
requirements to achieve BP management targets and include 
human, physical and intellectual resources, healthcare delivery, 
healthcare recipients, financing, and governance and information 
systems.
With global information technology tools available, the 
suggestion of using e-health, particularly m-health, for patient 
education is a very feasible approach in the guidelines. If  
well applied, this could be a useful tool in hypertension 
control. This roadmap is anticipated to substantially bridge 
the gap between HIC and LMIC in terms of hypertension 
management and control policy. The WHO Package of 
Essential Non-communicable (PEN) Disease Interventions for 
Primary Healthcare in Low-Resource Settings is an integrated 
approach to NCDs focusing exclusively on primary healthcare 
in low-resource settings.12 
The WHF roadmap provides a global framework to reduce 
CVD mortality, focusing on evidence-based interventions. 
Strong emphasis is placed on health systems, cost-effectiveness 
and subsequent evaluation of programmes. Hypertension as a 
single risk factor, and an entry point to prevent CVD rather than 
the absolute-risk approach, provides a framework to identify 
roadblocks in implementing evidence-based interventions. 
Hypertension seldom occurs in isolation, co-existing with other 
CVD risk factors, contributing to the absolute-risk status. 
The PASCAR roadmap strongly emphasises hypertension as a 
global health crisis and major threat. We hope that hypertension 
screening will increase in the next eight years, resulting in a 
paradoxical increase in the prevalence of hypertension. For this 
reason, the task force’s target is to increase treatment and control 
rates among the treated subjects by 25% in the SSA region by 2025.
We identified roadblocks to the control of hypertension in 
the African region and proposed solutions to these roadblocks, 
thus defining the best strategy to achieve this in SSA. Because 
the epidemic of NCDs is driven by globalisation, urbanisation, 
demographic trends and socio-economic conditions,13 
interventions to reach our targets are required from the health 
sector and other governmental sectors, along with civil society 
and the private sector. 
Therefore, guidance is provided for policy makers, healthcare 
professionals (nurses, general practitioners, family doctors, 
internists, cardiologists, nephrologists and other hypertension 
specialists), patients, the private sector and the public, including 
Prevalence 30%
(27–34%)
Awareness 27%
(7–56%)
Not aware
73%
Treated 18%
(14–22%)
Untreated
82%
Controlled* 7%
(5–8%)
Uncontrolled
93% *BP < 140/90 mmHg
Fig. 3.  Prevalence, awareness, treatment and control of 
hypertension in Africa. Numbers are from Ataklte et al. 
Burden of undiagnosed hypertension in sub-Saharan 
Africa: A systematic review and meta-analysis.5
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civil society, on controlling hypertension to reduce premature 
mortality from CVD. To guide the action of stakeholders, we 
also highlight the importance of reaching minimum standards 
(Table 3) for the health systems of countries to achieve the 25% 
hypertension control target. Implementation of these solutions 
and suggestions on customising the overall strategy at a country 
level are discussed.
The WHF roadmap provides a general framework that 
could be useful for LMICs, however, to be implemented it 
should be customised according to the local context. With 
PASCAR’s leadership and the contribution of other professional 
organisations, this approach seems to be at the right time to 
turn the many hypertension challenges in Africa into immense 
opportunities. Although population-based strategies for lowering 
BP may be cost-effective, they are not the focus of this roadmap, 
but we recognise these would be beneficial.
Methods
In January 2014, panel members who were appointed to develop 
the PASCAR roadmap were invited to join the PASCAR task 
force on hypertension. Based on their expertise and leadership 
in hypertension, 41 nominees from 21 countries received 
invitations, with 95% responding positively. These experts 
included cardiologists, nephrologists, public health physicians, 
researchers (including clinical trialists), nurses, pharmacologists, 
evidence-based medicine specialists and guideline developers. 
During the first face-to-face meeting held in Nairobi on 27 
October 2014,14 the group acknowledged the lack of a continental 
strategy to address the hypertension crisis. A decision was taken 
to develop a roadmap for the prevention and management of 
hypertension in Africa as a matter of urgency under the auspices 
of the WHF. 
To customise the WHF BP roadmap for Africa, the core 
group performed a comprehensive literature search and 
communicated with the WHF from November 2014 to July 2015 
via teleconference and e-mail. After receiving and comprehending 
the WHF roadmap document, task force members held a second 
face-to-face meeting in London on 30 August 2015, to make 
suggestions on its relevance and customisation. A detailed 
presentation of this roadmap was reviewed and discussed by 
PASCAR task force members, hypertension experts and leaders 
of hypertension societies via e-mail, with WHF feedback. 
Development of a warehouse for African guidelines and 
clinical trials on hypertension was also reviewed. Finally, the 
steps in developing the African roadmap for reducing CVD 
mortality rates through BP control was planned. 
The first draft of the PASCAR roadmap for hypertension 
management and control was presented in Mauritius on 4 
October 2015. Attendees were 13 presidents of national cardiac 
societies or representatives, the president of the International 
Forum for Hypertension Control and Cardiovascular Disease 
Prevention in Africa and representative of the International 
Society of Hypertension, a representative of the African Heart 
Network, members of the PASCAR task force on hypertension, 
and scientists from the WHF. The draft was reviewed and oral 
and e-mail comments were received from participants. The 
WHO PEN programme12 was compared with the PASCAR 
hypertension roadmap to ensure complementarity between the 
two documents.
Table 3. Minimum care for hypertension management  
at each healthcare level in Africa
Basic staff, equipment, test 
and medication
Level of care
Primary Secondary Tertiary
Trained health 
worker or nurse
Medical 
Practitioner Specialist
Basic equipment
Automated blood pressure 
devices, or calibrated 
sphygmomanometer, either 
mercury or oscillometric 
plus appropriate cuffs
+++ +++ +++
Home blood pressure 
devices + +++
Ambulatory blood 
pressure devices +/– +++
Tape measure for waist 
circumference +++ +++ +++
Scale for weight +++ +++ +++
Stadiometer for height +++ +++ +++
Standard 12-lead ECG ++ +++
Glucometer + +++ +++
Funduscope ++ +++
Stethoscope +++ +++ +++
Basic tests
Urine dipsticks for 
protein, blood and glucose +++ +++ +++
Standard 12-lead ECG 
recording ++ +++
Glucometer strips for 
testing glucose + +++ +++
Na+, K+ and creatinine 
with calculation of eGFR + ++ +++
Cholesterol + +++
Glycated haemoglobin 
(HbA1c)
+ ++ +++
Chest radiograph +/– +++
Basic medication classes with examples*
Thiazide or thiazide-like 
diuretic (hydrochloro-
thiazide, indapamide, 
chlorthalidone)
+++ +++ +++
Calcium channel blockers 
(amlodipine, nicardipine, 
long-acting nifedipine)
+++ +++ +++
Angiotensin converting 
enzyme inhibitor 
(enalapril, lisinopril, 
perindopril, ramipril) 
+ +++ +++
Angiotensin receptor 
blockers (candesartan, 
valsartan, losartan) 
+++ +++
Vasodilating beta-blockers 
(nebivolol, bisoprolol, 
carvedilol) 
+++ +++
Spironolactone +++ +++
Long-acting α-blocker 
(doxazocin)
+ +
Combinations of blood 
pressure-lowering 
medications
+ +++ +++
+++: strongly recommended; ++ moderately recommended, +: 
recommended; –: not done; +/–: done if  facilities are available.
*Availability of drugs at each level of care has been indicated and 
recommended here for initiation only, all drugs can be used once 
initiated by a medical practitioner.
A trained healthcare worker may initiate and follow up some medication.
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The second version of the roadmap draft was submitted to a 
core group for internal review from October to December 2015. 
In March 2016, a selected group of hypertension experts from 
12 French-speaking countries met in Yaoundé to discuss the 
algorithm and the draft.15 Comments were received and the draft 
was amended. 
The task force reviewed the final draft of the roadmap in 
Mexico in June 2016, which was then submitted for external 
peer-review by three independent experts in hypertension and 
policy development. The subsequent review was done by a group 
of experts in cardiology, nephrology, primary care and research 
(including clinical trials). Comments were reviewed and discussed 
by the panel and incorporated into a revised and final document.
PASCAR searches and surveys on the status of 
hypertension policy programmes and clinical 
practice guidelines
From May to July 2015, an internal PASCAR survey was 
conducted, aiming to determine which African countries ran 
hypertension control programmes focusing on policy. Using the 
Survey Monkey software tool,16 national hypertension experts 
from 40 countries were asked whether a hypertension policy 
programme was operating in their country and could be judged as 
being ‘dormant’, ‘not much active’, ‘active’, or ‘very much active’.
Among the responders (n = 127) representing 27 SSA countries, 
we noticed that up to 63.7% did not have a hypertension policy 
programme or that it was dormant or not very active. This 
regrettable situation highlights the importance of a continental 
initiative to develop a hypertension policy to address BP control 
from a population-wide and high-risk approach. 
Evidence has shown that explicit clinical practice guidelines 
(CPGs) do improve the care gap by providing practitioners and 
health-service users with synthesised quality evidence regarding 
decision-making.17 In another PASCAR study, we assessed 
the existence, development and use of national guidelines for 
the detection and management of hypertension in the African 
region, regardless of quality. 
Between May and July 2015, CPGs for hypertension were 
searched, using a scientifically developed search strategy. 
Searches were done using Google and PubMed. Search terms 
included (country name) AND (hypertension OR HTN OR 
high blood pressure) AND (clinical practice guidelines OR 
treatment guide). French, Portuguese and Spanish translations 
were included in the search strategy. 
Websites of ministries of health, national medical associations 
and the WHO were hand-searched, authors were e-mailed, and 
requests were sent on Afronets to obtain copies of CPGs for 
hypertension. To be included in the search, the CPGs had to be 
available and provided in full-text versions for assessment by the 
review team, comprising three independent authors. CPGs from 
Europe or South America or those that could not be obtained 
were considered non-existent. Two national hypertension experts 
were contacted for confirmation on countries for which we 
could not find CPGs on hypertension. CPGs published in peer-
reviewed journals needed to be readily accessed by end-users. 
E-mail messages were used for further clarification.
In Fig. 4, the 2015 map is presented of countries with clear 
evidence of the existence of national guidelines for detection 
and management of BP across Africa. Only 16 (25.8%) out of 
62 countries had CPGs complying with our search criteria. No 
evidence of CPGs on hypertension management could be found 
for the other 46 (74.2%) countries. Given that the only existing 
multinational expert recommendations for the management of 
hypertension in Africa dates back to 2003 and has not been 
updated since,18 we concluded that there is a legitimate, pressing 
need to support African ministries of health with a clear 
hypertension roadmap. 
PASCAR roadmap to decrease the burden of 
hypertension in Africa 
To reduce the incidence of CVD through treating hypertension 
in the African region, it will be necessary to increase the rates of 
detection, treatment and control of the disease. The 10 actions 
that need to be undertaken by African ministries of health to 
achieve a 25% control of hypertension in Africa by 2025 (Fig. 4) 
are listed below and we include an explanation as to why (bullets) 
and how (dashes) this needs to be done. 
1. All NCD national programmes should additionally contain 
a plan for the detection of hypertension.
•	 The hypertension crisis has yet to receive an appropriate 
response in SSA.19 
•	 Incidence of hypertension increased by 67% since 1990 
and was estimated to cause more than 500 000 deaths and 
10 million years of life lost in 2010 in SSA.20,21 
•	 Hypertension is the main cause of stroke, heart failure and 
renal disease in SSA.
•	 Stroke, which is a major complication of uncontrolled 
hypertension, has increased to 46% since 1990 and essen-
tially affects breadwinners.20
•	 Failure to control hypertension and its economic repercus-
sions through revising health policies and services endan-
gers the economic prosperity of all African nations.22
Fig 4.  2015 map of African countries with evidence of existing 
clinical practice guidelines for hypertension manage-
ment and 10 actions to reduce the hypertension 
burden in Africa 
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 – All SSA countries should have adopted and should 
follow the WHO global agenda of reducing NCDs by 
2020. 
 – When reporting to the Ministry of Health and the 
WHO, stakeholders should report specifically on hyper-
tension.
 – National cardiac and hypertension societies should 
monitor the prevalence, awareness and control rates of 
hypertension and report to PASCAR.
 – Government, private sector, academia and community 
organisations should pay attention to this report and 
work together for a reduction in hypertension preva-
lence.
2. Allocate appropriate funding and resources for the early 
detection, efficient treatment and control of hypertension.
•	 The costs of priority interventions for NCDs, including 
hypertension, have been shown to be small and countries 
are receiving global funds.
•	 No new global funding is needed to implement the 10 
actions for controlling hypertension.
•	 Comprehensive implementation to control hypertension 
and reduce salt intake is affordable in all countries.
•	 The current increasing burden of uncontrolled hyperten-
sion is a barrier to the development of all African nations.
•	 Funding to support civil society and health organisations 
will contribute to developing and implementing appropri-
ate health policies to control hypertension.
•	 Funding is needed to support dissemination of best prac-
tices to detect, manage and control NCDs within Africa. 
 – Increase healthcare budgets in Africa to align with 
the WHO global action plan of 2013–2020, which has 
already been adopted by all SSA countries.
 – Realign existing funding with the emerging hyperten-
sion threat that SSA populations are experiencing. 
 – Dedicate a clear percentage of the health budget to 
hypertension policy.
 – Use existing resources more efficiently. 
 – Develop innovative funding mechanisms, including 
additional alcohol and tobacco taxes. 
 – National cardiac and hypertension societies should 
monitor the hypertension/NCD-related budget every 
two years and advocate otherwise for improvement.
3. Create or adopt simple and practical clinical evidence-based 
hypertension management guidelines.
•	 The role of simple and practical guidelines is crucial for 
managing NCDs at large, and hypertension specifically.
•	 In 2015, only 25% of SSA countries had developed or 
adopted clinical guidelines for managing hypertension 
(Fig. 4).
•	 New scientific knowledge guides implementation and 
efficiency in developing guidelines according to the best 
actual practices.
 – PASCAR will develop and regularly update continen-
tal guidelines with a simple care algorithm (Fig. 2) 
for detecting, treating and controlling hypertension. 
National cardiac societies are called upon to adopt or 
adapt to the country’s circumstances where appropriate.
 – Alternatively, the WHO HEARTS technical package 
for CVD management in primary healthcare overtakes 
WHO PEN12 and provides a comprehensive CVD 
control approach,23 with the possibility of integrating 
hypertension as a risk factor.
 – PASCAR has defined and will regularly update the mini-
mum standards (Table 3) to control hypertension, which 
need to be achieved by each SSA country. Countries are 
called upon to adopt and implement these.
4. Annually monitor and report the detection, treatment and 
control rates of hypertension, with a clear target of improve-
ment by 2025, using the WHO STEPwise surveillance in all 
countries.
•	 The success of all NCD interventions, including hyper-
tension policy, will depend on how specific, measurable, 
achievable, realistic and time-bound the objectives are.
•	 A framework for national and continental monitoring, 
reporting and accountability will ensure that the returns 
on investments in hypertension and other NCDs meet the 
expectations of all partners. 
 – The WHO STEPwise approach to NCD risk-factor 
surveillance should be strengthened in all African coun-
tries to report on detecting, treating and controlling 
hypertension annually.
 – BP to be measured at all relevant clinical encounters.  
 – Regular representative population surveys are effective 
in monitoring trends of key risk factors and the uptake 
of priority interventions, such as the WHO STEPS 
approach to monitor NCD risk factors.
 – National cardiac and/or hypertension societies should 
measure the level of coverage for some sentinel sites 
(communities, industries, primary healthcare centres, 
etc.) and report to PASCAR.
 – National cardiac and/or hypertension societies should 
take responsibility for reporting progress in hyperten-
sion control, mobilising resources, developing policy 
and identifying best practices.
 – The monitoring and reporting team in sentinel sites will 
ensure that people know their BP, hypertensives receive 
appropriate treatment, BP is controlled and they remain 
on treatment.
5. Integrate hypertension detection, treatment and control 
within existing health services, such as vertical programmes 
(e.g. HIV, TB).
•	 What the medical community learned from the large-scale 
management of TB and HIV/AIDS should be successful in 
managing hypertension. 
 – The government, private sector, academia and commu-
nity organisations should work together to align plans 
for detecting, treating and controlling hypertension 
with other ongoing programmes.
 – Emphasis should be placed on (1) standardised treat-
ment protocols, (2) identification and availability of 
affordable and effective drugs, and (3) service delivery, 
as with TB and HIV programmes.
6. Promote a task-sharing approach with adequately trained 
community health workers (shift-paradigm).
•	 SSA carries 11% of the world population, 25% of the 
global burden of disease, with only 3% of the world’s 
health labour force, and has a global health expenditure 
of less than 1%.24
•	 These health-worker shortages are a major barrier to 
controlling hypertension in Africa.
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•	 Clear evidence exists that health staff without formal 
professional training can be adequately trained to effec-
tively detect people with severe hypertension.25 
•	 Using trained community health workers (CHW) to detect 
hypertension would free health professionals in Africa to 
treat and control the condition. 
•	 Well-trained nurses, general and family physicians can 
adequately manage uncomplicated hypertension, freeing 
specialists for more severe cases. 
 – Design a course to train CHW in detecting hyperten-
sion, providing information and educating the commu-
nity.
 – Train 250 000 CHW to detect hypertension by 2025.
 – Design special courses reinforcing health staff capacity 
to manage hypertension.
 – Use an online system to train at least 50 000 certified 
nurses and 25  000 certified general physicians to take 
appropriate decisions regarding detecting, treating and 
controlling hypertension by 2025.
 – PASCAR and national cardiac societies will design the 
course, and national recertification may be required 
after training.
7. Ensure the availability of essential equipment and medicines 
for managing hypertension at all levels of care.
•	 Target 8 of the global action plan acknowledges the need 
to improve the availability of affordable BP machines and 
medicines for the poor.26
•	 Target 9 of the global action plan is an 80% availability 
of affordable basic technologies and essential medicines, 
including generics, required to treat major NCDs in public 
and private facilities.26 
•	 Access to affordable and good-quality drugs for hyperten-
sion is important for all LMICs, and especially SSA.26 
 – Governments and societies should be willing to priori-
tise hypertension control and provide low-cost BP 
machines and medications.
 – PASCAR and national cardiac and hypertension socie-
ties have adopted a hypertension treatment algorithm, 
suggesting the use of high-quality antihypertensive 
medications (Fig. 2).
 – The ongoing randomised clinical trial, Comparing 
Three Combination Therapies in Lowering Blood 
Pressure in Black Africans (Creole), will provide more 
evidence-based information on the most efficacious of 
three ‘free’ combinations of two antihypertensive agents 
on 24-hour ambulatory systolic BP.27 
 – PASCAR has defined minimum standards for BP 
machines and drug availability and affordability to 
control hypertension in Africa (Table 3).
 – PASCAR and national cardiac and hypertension 
societies should strongly advocate making antihyper-
tensive medications available and more affordable to 
patients. 
 – Governments should encourage adding to and peri-
odically updating the hypertension medications on their 
national essential medicine list.
 – Governments should subsidise the cost of and remove 
import duties on these essential medications.
 – Governments should put in place an efficient, high-
quality monitoring process of medicines.
 – Donor organisations and pharmaceuticals should be 
engaged in making these medications affordable.
 – PASCAR will regularly measure the proportion of the 
population with access to affordable, essential drugs in 
sentinel sites. 
8. Provide universal access and coverage for detecting, treating 
and controlling hypertension.
•	 There are proven cost-effective lifestyle and medical inter-
ventions to prevent and manage hypertension. However, in 
Africa, uptake is still unacceptably low.3
•	 Universal health coverage will be the main step forward to 
ensure that persons with hypertension have access to effec-
tive, affordable and accessible care.
 – Governments must have the political will to acknowl-
edge the hypertension crisis, and the commitment to 
convince their parliaments to approve budgets needed 
for universal coverage.
 – Failure to implement universal coverage may result in 
increased healthcare expenditure on the complications 
of hypertension.
9. Support high-quality research to produce the evidence that 
will guide interventions.
•	 Data from randomised, controlled trials on hypertension 
management are lacking in SSA.
•	 Research is vital in formulating a sound healthcare policy 
to evaluate the performance of interventions in hyperten-
sion control and take managerial decisions in the overall 
NCD policy.28
•	 Research into hypertension in Africa should be essential, 
especially where it can inform resource-allocation deci-
sions.
 – African governments should encourage all multidisci-
plinary, multidirectional and collaborative approaches 
at national and international levels, and take a firm 
commitment to develop research guided through prior-
ity intervention, as suggested by the WHO.26
 – National cardiac and/or hypertension societies should 
take responsibility for identifying research priorities, 
building national and international research networks 
and partnerships, and advocating for investment in 
research to support best practices. 
 – PASCAR, with its good continental research network, 
will continue taking the leadership for research train-
ing and funding while ensuring to develop and sustain 
research activities to guide cost-effective interventions 
for hypertension control.
10. Invest in population-level interventions for preventing hyper-
tension, such as reducing salt intake and obesity levels, 
increasing fruit and vegetable intake and promoting physical 
activity.
•	 The relationship between BP and the risk of developing 
stroke or heart disease is ongoing, starting at a systolic 
pressure > 115 mmHg.1 
•	 Hypertension is a preventable cause of morbidity and 
mortality. 
•	 High-quality evidence in non-acutely ill adults shows that 
reduced sodium intake reduces BP.29
•	 These two previous facts highlight the importance of high-
risk and population-based strategies in BP management 
and control.
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 – Therefore, advocate for a healthy public policy and 
large national programme for hypertension prevention 
and control. 
 – Use national multi-sectoral policies and plans that 
specifically address physical activity and nutrition, 
including dietary salt, in preventing hypertension and 
NCDs.
 – Wider implementation of  successful governmental 
actions including smoke-free policies, marketing of 
unhealthy foods and alcohol, sin taxes (e.g. sugar 
taxes), and regulation of sodium content in processed 
foods. 
How to adapt the PASCAR 10 actions at country 
level
This roadmap can be implemented as is or adapted to overcome 
local barriers and develop solutions that are more relevant 
to speciﬁc national settings. In the latter case, we recommend 
that national roadmaps be developed, using a multi-sectoral 
approach in collaboration with inter-governmental organisations, 
heart health advocacy foundations, cardiovascular scientiﬁc 
organisations, healthcare leaders, providers from primary and 
specialised care, private-sector stakeholders and people affected 
by CVD. 
Effective advocacy towards policy-makers and politicians in 
national governments is mandatory for success. Screening among 
politicians might be an effective way to increase awareness and 
encourage governments to act. 
The PASCAR task force recommended the following steps:
•	 Step 1: where applicable, national cardiac societies (otherwise 
national hypertension societies or cardiovascular specialists) 
should take the leadership to develop and convene a multi-
sectoral coalition against hypertension. At this step, persuad-
ing the government and all other stakeholders to collaborate 
is essential.
•	 Step 2: this coalition will then assess the epidemiological 
profile of hypertension and review and synthesise existing 
ofﬁcial data and published and unpublished literature. This 
step also includes a map of all existing policies.
•	 Step 3: the coalition conducts policy dialogues with multiple 
local stakeholders. Local problems, speciﬁc barriers to hyper-
tension control and potential solutions should be discussed 
and appropriate strategies selected according to context. At 
this step, it is important to understand existing policies and 
their current effect. Within the same nation, appropriate 
strategies may also need adaptation. Some stakeholders who 
will be invited to the policy dialogue include the ministry of 
health, various health sector staff (physicians and non-physi-
cians), health workers, key opinion leaders such as politicians 
and religious people, and also alternative medicine specialists 
and traditional healers, who may have a significant influence 
on people with hypertension in some settings. 
•	 Step 4: the coalition develops a clear national strategy and 
time-bound plan for detecting, treating and controlling hyper-
tension.
The PASCAR coalition against hypertension takes responsibility 
for fostering the development of  national roadmaps and 
supporting national cardiac and hypertension societies at all 
levels. 
Conclusions 
Although there is significant scientific evidence that cost-
effective lifestyle and medical interventions could control 
hypertension and prevent health-threatening complications, 
such as heart disease and stroke, the African region still bears 
a very high disease prevalence, coupled with poor rates of 
detection, treatment and control. This context is a barrier to 
the achievement of the universal global action plan and gives 
reasons for urgent action. 
The PASCAR task force on hypertension roadmap was 
conceived by a variety of leaders and stakeholders in the field 
to provide the most appropriate strategy to have 25% control of 
hypertension by 2025. The roadmap identifies major barriers to 
disease control and priority areas of intervention, and 10 actions 
to improve the control of hypertension by 2025 are proposed. 
The most important steps to put forth in this continental 
roadmap include: 
1. Advocate for government leadership and policy.
2. Allocate funding and resources.
3. Design simple and practical guidelines.
4. Promote large-scale screening. 
5. Integrate hypertension detection, treatment and control in all 
existing programmes.
6. Promote task sharing and expand the scope of practice. 
7. Promote the use of inexpensive, good-quality BP machines 
and generic medications. 
8. Promote universal coverage for hypertension diagnosis and 
management.
9. Support high-quality research to produce the best evidence 
for interventions.
10. Invest in population preventive measures. 
This is a unique moment in history for the African CVD 
community to have worked with global leaders in the field 
in defining a clear agenda to address the hypertension crisis. 
Support for this programme from the African Union and 
all stakeholders will help achieve the WHO global action 
plan of 2013–2020 for NCD reduction, specifically focusing 
on heart attack, stroke and other CVDs. The WHO and 
other UN organisations will support national efforts with 
upstream policy advice and sophisticated technical assistance, 
ranging from assisting governments to setting national targets 
in implementing relatively simple steps, which can make a huge 
difference.
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